Figure 3From: Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial) Event-free survival of major adverse cardiovascular events. Major adverse cardiovascular events (MACE) were defined as death, nonfatal myocardial infarction, symptomatic recurrent ischemia, or urgent revascularization.Back to article page